Literature DB >> 3753004

The effect of 2,3-diphosphoglycerate on the solubility of deoxyhemoglobin S.

W N Poillon, B C Kim, E V Welty, J A Walder.   

Abstract

Although highly charged polyanions, such as inositol hexaphosphate, have been clearly shown to decrease the solubility of deoxyhemoglobin S, the effect of 2,3-diphosphoglycerate (DPG), the endogenous allosteric effector within the red cell, has been more controversial. In this work we have compared the effect of DPG on the solubility of native deoxyhemoglobin S and a derivative in which the DPG binding site is blocked by cross-linking the two beta 82 lysine residues. At pH 6.6 and 30 degrees C the solubility of deoxyhemoglobin S was found to be decreased by 15% (i.e., from 18.8 to 16.0 g/dl) in the presence of saturating concentrations of DPG. Under the same conditions DPG had no effect on the solubility of the cross-linked derivative. This result establishes unequivocally that the binding of DPG within the beta cleft directly facilitates the polymerization of deoxyhemoglobin S. Under physiological conditions, the solubility of deoxyhemoglobin S was found to be decreased by 6% in the presence of an equimolar concentration of DPG. A solubility decrease of this magnitude is sufficient to enhance the tendency of SS cells to sickle and may exacerbate the clinical symptoms of sickle cell disease.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3753004     DOI: 10.1016/0003-9861(86)90006-8

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  9 in total

1.  Dynamics of oxygen unloading from sickle erythrocytes.

Authors:  V B Makhijani; G R Cokelet; A Clark
Journal:  Biophys J       Date:  1990-10       Impact factor: 4.033

2.  Detrimental effects of adenosine signaling in sickle cell disease.

Authors:  Yujin Zhang; Yingbo Dai; Jiaming Wen; Weiru Zhang; Almut Grenz; Hong Sun; Lijian Tao; Guangxiu Lu; Danny C Alexander; Michael V Milburn; Louvenia Carter-Dawson; Dorothy E Lewis; Wenzheng Zhang; Holger K Eltzschig; Rodney E Kellems; Michael R Blackburn; Harinder S Juneja; Yang Xia
Journal:  Nat Med       Date:  2010-12-19       Impact factor: 53.440

3.  Rational modification of vanillin derivatives to stereospecifically destabilize sickle hemoglobin polymer formation.

Authors:  Tanvi M Deshpande; Piyusha P Pagare; Mohini S Ghatge; Qiukan Chen; Faik N Musayev; Jurgen Venitz; Yan Zhang; Osheiza Abdulmalik; Martin K Safo
Journal:  Acta Crystallogr D Struct Biol       Date:  2018-10-02       Impact factor: 7.652

4.  Identification of a novel class of covalent modifiers of hemoglobin as potential antisickling agents.

Authors:  A M Omar; M A Mahran; M S Ghatge; N Chowdhury; F H A Bamane; M E El-Araby; O Abdulmalik; M K Safo
Journal:  Org Biomol Chem       Date:  2015-06-14       Impact factor: 3.876

5.  FT-4202, an oral PKR activator, has potent antisickling effects and improves RBC survival and Hb levels in SCA mice.

Authors:  Archana Shrestha; Mengna Chi; Kimberly Wagner; Astha Malik; Jennifer Korpik; Adam Drake; Keertik Fulzele; Sylvie Guichard; Punam Malik
Journal:  Blood Adv       Date:  2021-05-11

Review 6.  Adenosine signaling in normal and sickle erythrocytes and beyond.

Authors:  Yujin Zhang; Yang Xia
Journal:  Microbes Infect       Date:  2012-05-23       Impact factor: 2.700

Review 7.  Therapeutic strategies to alter the oxygen affinity of sickle hemoglobin.

Authors:  Martin K Safo; Gregory J Kato
Journal:  Hematol Oncol Clin North Am       Date:  2014-01-21       Impact factor: 3.722

Review 8.  New developments in anti-sickling agents: can drugs directly prevent the polymerization of sickle haemoglobin in vivo?

Authors:  Esther Oder; Martin K Safo; Osheiza Abdulmalik; Gregory J Kato
Journal:  Br J Haematol       Date:  2016-09-08       Impact factor: 6.998

Review 9.  Metabolic Reprogramming in Sickle Cell Diseases: Pathophysiology and Drug Discovery Opportunities.

Authors:  Dina Alramadhani; Anfal S Aljahdali; Osheiza Abdulmalik; B Daniel Pierce; Martin K Safo
Journal:  Int J Mol Sci       Date:  2022-07-04       Impact factor: 6.208

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.